Globally operating CDMO committed to strengthening Germany as a research and production location
Association grants Vetter extraordinary membership
vfa recognizes the importance of pharmaceutical service providers in drug development and production
Vetter serves on key vfa committees
RAVENSBURG, Germany, January 17, 2024. Vetter, a leading globally operating contract development and manufacturing organization (CDMO), has joined the German Association of Research-Based Pharmaceutical Companies (vfa) as an associate member. With this membership, the vfa recognizes the significantrole that the pharmaceutical service provider plays in the field of complex injectable drugs. Vetter supports research-based pharmaceutical companies worldwide in successfully developing, launching, and establishing their products on the market through thejoint development of patient-friendly drug-delivery systems, innovative and flexible filling processes, and packaging solutions. Currently at 48 member companies, the vfa represents more than two thirds of the entire German pharmaceutical market. The companiesemploy around 94,000 people in Germany. More than 20,000 of them work in the research and development of medicinal products.
Managing Director Peter Soelkner stated, "It is a great recognition for us that the vfa has invited us to participate. The association is the most importantplatform for pharmaceutical companies active in Germany to promote and support the strategic development of the industry and further establish Germany as an important business location. We can now also contribute our perspective here. As a globally operatingCDMO, we play an important role as a partner for small and large companies in the industry."
Aside from its headquarters and several sites for development, aseptic production and packaging in Germany, Vetter also operates dedicated clinical production sites in Austria and the US, along with sales offices in Japan, Singapore, SouthKorea and China. Through its international presence, Vetter provides state-of-the-art support from clinical development through large-scale production as well as assembly and packaging for complex injectable drug products in the global market supply.
Han Steutel, President of the vfa said, "The production of injectable drugs is an indispensable part of the innovative pharmaceutical and biotech industries.We are delighted that Vetter, a global leader in this field, is a member of the vfa."
Active involvement in committee work
The association's work is carried out by committees and working groups focusing on specific topics. Managing Director Peter Soelkner will represent Vetter in the Committee for Economic and Business Location Policy. Dr. Claus Feussner,Senior Vice President Development Service, has been appointed to the Research and Development Committee. Vetter experts will also collaborate in the expert groups regulatory affairs, manufacturing, innovation and communication.
By joining the vfa, Vetter becomes a member of organizations such as the German Chemical Industry Association (VCI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The EFPIA plays a key role in fosteringcooperation and synergy among member countries to strengthen and develop research and production capabilities at EU level.